No data to show
XTAE
MTLF
Market cap12mUSD
Apr 07, Last price
281.30ILS
1D
0.11%
1Q
-26.55%
IPO
-55.85%
Name
Matricelf Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-12m
L-23.60%
CFO
-8m
L+25.27%
Profile
Matricelf Ltd, a biotechnology company, develops a platform for autologous matrix and cells implants for various medical conditions. Its regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction, as well as for 3D organ printing. Matricelf Ltd was founded in 2019 and is based in Ness Ziona, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 9,091 | |||
Unusual Expense (Income) | ||||
NOPBT | (9,091) | |||
NOPBT Margin | ||||
Operating Taxes | (239) | |||
Tax Rate | ||||
NOPAT | (8,852) | |||
Net income | (12,486) -23.60% | |||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 19,963 | |||
BB yield | -34.09% | |||
| Debt | ||||
Debt current | 335 | |||
Long-term debt | 907 | |||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (32,067) | |||
| Cash flow | ||||
Cash from operating activities | (8,298) | |||
CAPEX | (602) | |||
Cash from investing activities | (31,665) | |||
Cash from financing activities | 19,517 | |||
FCF | (8,469) | |||
| Balance | ||||
Cash | 33,217 | |||
Long term investments | 92 | |||
Excess cash | 33,309 | |||
Stockholders' equity | (10,730) | |||
Invested Capital | 47,766 | |||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 13,123 | |||
Price | 4.46 -48.14% | |||
Market cap | 58,556 -21.81% | |||
EV | 26,489 | |||
EBITDA | (8,280) | |||
EV/EBITDA | ||||
Interest | 163 | |||
Interest/NOPBT | ||||